Bolli Niccolò, Martinelli Giovanni, Cerchione Claudio
Department of Oncology and Hemato- Oncology, University of Milan, Italy.
Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Hematol Rep. 2020 Dec 18;12(3):9054. doi: 10.4081/hr.2020.9054. eCollection 2020 Dec 2.
Multiple Myeloma (MM) is characterized by uncontrolled proliferation and accumulation of clonal plasma cells within the bone marrow. However, the cell of origin is a B-lymphocyte acquiring aberrant genomic events in the germinal center of a lymph node as off-target events during somatichypermutation and class-switch recombination driven by activation-induced-deaminase. Whether pre-germinal center events are also required for transformation, and which additional events are required for disease progression is still matter of debate. As early treatment in asymptomatic phases is gaining traction in the clinic, a better understanding of the molecular pathogenesis of myeloma progression would allow stratification of patients based on their risk of progression, thus rationalizing efficacy and cost of clinical interventions. In this review, we will discuss the development of MM, from the cell of origin through asymptomatic stages such as monoclonal gammopathy of undetermined significance and smoldering MM, to the development of symptomatic disease. We will explain the genetic heterogeneity of MM, one of the major drivers of disease recurrence. In this context, moreover, we will propose how this knowledge may influence future diagnostic and therapeutic interventions.
多发性骨髓瘤(MM)的特征是骨髓内克隆性浆细胞不受控制地增殖和积聚。然而,其起源细胞是一种B淋巴细胞,在生发中心获得异常基因组事件,这些事件是由激活诱导脱氨酶驱动的体细胞超突变和类别转换重组过程中的脱靶事件。生发中心前事件是否也是转化所必需的,以及疾病进展还需要哪些其他事件,仍是一个有争议的问题。随着无症状期的早期治疗在临床上越来越受到关注,更好地了解骨髓瘤进展的分子发病机制将有助于根据患者的进展风险对其进行分层,从而使临床干预的疗效和成本合理化。在这篇综述中,我们将讨论MM的发展,从起源细胞到无症状阶段,如意义未明的单克隆丙种球蛋白病和冒烟型MM,再到有症状疾病的发展。我们将解释MM的遗传异质性,这是疾病复发的主要驱动因素之一。此外,在这种背景下,我们将提出这些知识可能如何影响未来的诊断和治疗干预。